Propanc Biopharma Inc. has entered into a Securities Purchase Agreement with Hexstone Capital LLC for a private placement of Series C Preferred Stock. The agreement includes the issuance of 100 shares of Series C Preferred Stock and a warrant to purchase up to 9,900 additional shares, with conversion terms linked to the company's common stock trading price. Completion of the deal is subject to certain closing conditions, including the filing of a Certificate of Designation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018054), on October 14, 2025, and is solely responsible for the information contained therein.